142 related articles for article (PubMed ID: 2592365)
1. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
2. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
4. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
Beardsley GP; Moroson BA; Taylor EC; Moran RG
J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
[TBL] [Abstract][Full Text] [Related]
5. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
6. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
Lehman NL
Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
8. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
9. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
10. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
[TBL] [Abstract][Full Text] [Related]
11. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
Sanghani SP; Moran RG
Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
[TBL] [Abstract][Full Text] [Related]
12. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
[TBL] [Abstract][Full Text] [Related]
14. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines.
Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP
J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
Kelley JL; McLean EW; Cohn NK; Edelstein MP; Duch DS; Smith GK; Hanlon MH; Ferone R
J Med Chem; 1990 Feb; 33(2):561-7. PubMed ID: 2299624
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
[TBL] [Abstract][Full Text] [Related]
17. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.
Mullin RJ; Keith BR; Bigham EC; Duch DS; Ferone R; Heath LS; Singer S; Waters KA; Wilson HR
Biochem Pharmacol; 1992 Apr; 43(7):1627-34. PubMed ID: 1567484
[TBL] [Abstract][Full Text] [Related]
19. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.
Itoh F; Russello O; Akimoto H; Beardsley GP
Cancer Chemother Pharmacol; 1994; 34(4):273-9. PubMed ID: 8033293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
